| CNS - SEL103 |
|
SEL103 program Alzheimer's disease is the most common cause of dementia. Dementia is a collective name for progressive degenerative brain syndromes which affect memory, thinking, behaviour and emotion. Although there are no drugs that can cure Alzheimer's disease, there are some treatments that can help people with Alzheimer's disease. However, better drug treatments are needed, especially due to the aging of human population. Currently there are an estimated 30 million people worldwide with dementia. Two thirds of them live in developing countries. This figure is set to increase to more than 100 million people by 2050. Selvita’s SEL103 program is based on novel, orally bioavailable and highly selective small-molecules which have the potential to play role in the treatment of multiple cognitive disorders, including Alzheimer’s disease, dementias, etc. Selvita is developing this project in parthership with Orion Corporation from Espoo, Finland (ORNBV). Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization. SEL103 is expected to enter formal pre-clinical development shortly. Copyright © 2007-2010 Selvita Sp. z o.o. |